CoChat

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index; 2 of the 12 sources its claims cite were checked for support.

Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms.

Open access
Schwartz, N S, Clutter, W E, Shah, S D, Cryer, P E · 1987 · Journal of Clinical Investigation

Abstract

To define glycemic thresholds for activation of glucose counterregulatory systems and for symptoms of hypoglycemia, we measured these during stepped reductions in the plasma glucose concentration (in six 10-mg/dl hourly steps) from 90 to 40 mg/dl under hyperinsulinemic clamp conditions, and compared these with the same measurements during euglycemia (90 mg/dl) under the same conditions over 6 h in 10 normal humans. Arterialized venous plasma glucose concentrations were used to calculate glycemic thresholds of 69 +/- 2 mg/dl for epinephrine secretion, 68 +/- 2 mg/dl for glucagon secretion, 66 +/- 2 mg/dl for growth hormone secretion, and 58 +/- 3 mg/dl for cortisol secretion. In contrast, the glycemic threshold for symptoms was 53 +/- 2 mg/dl, significantly lower than the thresholds for epinephrine (P less than 0.001), glucagon (P less than 0.001), and growth hormone (P less than 0.01) secretion. Thus, the glycemic thresholds for activation of glucose counterregulatory systems during decrements in plasma glucose lie within or just below the physiologic plasma glucose concentration range, and are substantially higher than the threshold for hypoglycemic symptoms in normal humans. These findings provide further support for the concept that glucose counterregulatory systems are involved in the prevention, as well as the correction, of hypoglycemia.

Overview

CoChat Summary

TL;DR

In normal humans, stepped hyperinsulinemic hypoglycemia showed that glucose counterregulatory hormone responses begin at higher plasma glucose levels than hypoglycemic symptoms. The authors conclude that counterregulatory systems are activated within or just below the physiologic glucose range, supporting their role in preventing as well as correcting hypoglycemia.

Key findings

  • Calculated arterialized venous glycemic thresholds were 69±2 mg/dl for epinephrine, 68±2 mg/dl for glucagon, 66±2 mg/dl for growth hormone, 58±3 mg/dl for cortisol, and 51±3 mg/dl for norepinephrine.
  • The symptom threshold was 53±2 mg/dl, significantly lower than thresholds for epinephrine (P < 0.001), glucagon (P < 0.001), and growth hormone (P < 0.01).
  • The cortisol threshold tended to exceed the symptom threshold but not significantly; the norepinephrine threshold was similar to the symptom threshold.
  • Mean symptom score began to increase during the 70–60 mg/dl step and clearly exceeded control values during the 60–50 mg/dl step.

Methods

  • Ten normal young adults (nine men, one woman; age 23–34 yr, mean±SD 26±3 yr) underwent two 6-h studies after an overnight fast: an experimental stepped-glucose study and a euglycemic control study.
  • Under hyperinsulinemic clamp conditions, plasma glucose was lowered in six 10-mg/dl hourly steps from 90 to 40 mg/dl in the experimental study, while the control study clamped glucose at 90 mg/dl; arterialized venous samples were drawn every 10 min, and symptoms were self-scored 0–10 for 12 symptoms.
  • Glycemic thresholds were calculated as the mean glucose concentration at which each parameter first exceeded the 95% confidence interval from euglycemic control data, after adjusting baseline data to zero; thresholds were compared with a t test.

Limitations

  • The authors state that thresholds were determined in a small, reasonably homogeneous group of normal young adults and should not be extrapolated uncritically to other conditions.
  • They note the thresholds are conservative estimates that may be lower than biologic thresholds because responses must have begun before values exceeded the 95% confidence intervals; inspection suggested epinephrine and growth hormone thresholds may be >70 mg/dl, perhaps >80 mg/dl.
  • They also state that arterialized venous values may not be comparable to venous glucose under other conditions, that cortisol’s lower threshold might reflect unmeasured ACTH response delay, and that steady state was not achieved in the control study; the design could not distinguish reduced plasma glucose per se from insulin resistance induced by counterregulatory activation.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1172/jci112884

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

1 Valid · 0 Not valid · 4 Not checked · 32 Own results and interpretations

17 more claims

Create a free account to see all 37 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 11
  • Probably not a substantial claim. 6

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

6 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 38 references

Cited by

See all 394

Metadata

Authors
Schwartz, N. S., Clutter, W. E., Shah, S. D., & Cryer, P. E.
Affiliations
Washington University in St. Louis (US)
Venue
Journal of Clinical Investigation
Published
1987-03-01
Volume
79
Issue
3
Pages
777-781
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2087707740
Cited by
394
References
38
Citations by year
2026: 10 · 2025: 5 · 2024: 8 · 2023: 9 · 2022: 14 · 2021: 11 · 2020: 6 · 2019: 6 · 2018: 13 · 2017: 13 · 2016: 10 · 2015: 12 · 2014: 12 · 2013: 13 · 2012: 12
FWCI
6.89
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5p60am020579-08, 2r01am027085-06)
  • National Center for Research Resources (RR.00036)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
hypoglycemia, glycemic thresholds, glucose counterregulation, hypoglycemic symptoms, epinephrine secretion, glucagon secretion, growth hormone secretion, cortisol secretion, hyperinsulinemic-euglycemic clamp, plasma glucose, hypoglycemia prevention
MeSH terms
Adult, Blood Glucose, C-Peptide, Epinephrine, Fatty Acids, Nonesterified, Female, Glucagon, Humans, Hydrocortisone, Hydroxybutyrates, Hypoglycemia, Insulin, Lactates, Male, Norepinephrine, Growth Hormone, Lactic Acid, 3-Hydroxybutyric Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. https://app.cochat.ai/papers/10.1172/jci112884
The paper
Schwartz, N. S., Clutter, W. E., Shah, S. D., & Cryer, P. E. (1987). Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. Journal of Clinical Investigation. https://doi.org/10.1172/jci112884

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.